e-Pharmatimes

HMPV (Human Metapneumovirus) is a common respiratory virus that can cause cold-like symptoms. In most cases, HMPV infection is mild and resolves on its own within a week or two. However, certain individuals, such as infants, older adults, and those with weakened immune systems, may experience more severe illness or complications. Medical attention for HMPV is typically recommended when symptoms are severe or persistent, or if there are concerns about complications. Here are some situations where you should seek medical attention for HMPV: * Difficulty breathing: This includes rapid breathing, wheezing, or shortness of breath. * High fever: A fever that is persistently high or doesn't respond to over-the-counter medications. * Dehydration: Signs of dehydration include decreased urination, dry mouth or skin, and dizziness. * Persistent cough: A cough that doesn't improve or worsens after a week or two. * Bluish lips or skin: This can be a sign of low oxygen levels. I...

Biogen, which was first to score an endorsement in Spinal Muscular Atrophy (SMA) in 2016, is endeavoring to address it with a higher portion variant of Spinraza #(Nusinersen). On Wednesday, the organization uncovered that a part of its stage 2/3 Commit concentrate on met its essential endpoint, as a higher portion of Spinraza worked on the engine capability of treatment-innocent newborn children with SMA. The review contrasted the high-portion routine with a coordinated, untreated hoax control bunch from the stage 3 Charm study, which empowered Spinraza's unique endorsement. In the Commit preliminary accomplice, 75 patients were randomized 2:1 to get the higher-portion routine or the FDA-endorsed dose of 12 mg, which incorporates four beginning medicines, trailed by support dosages like clockwork. While the high-portion form of Spinraza met the preliminary's endpoint contrasted with joke, the outcomes too "moved in favor" of the investigational routine contrasted with...

With AstraZeneca’s dominance in the rare blood disease paroxysmal nocturnal hemoglobinuria (PNH) threatened by the recent approval of the first pill on the market for the condition, Novartis’ Fabhalta, AstraZeneca has answered in the United States for its add-on oral treatment in the indication. The FDA has signed off on Voydeya (danicopan), a factor D inhibitor, to treat PNH patients with extravascular hemolysis (EVH), a condition that causes red blood cell destruction outside of the blood vessels. The nod comes three months after the Japanese Ministry of Health, Labour and Welfare (JHLW) became the first regulator worldwide to endorse the therapy. Voydeya works as an add-on for AZ’s pair of PNH standard-of-care blockbusters—Soliris, which has been on the market for 17 years and generated $3.2 billion in sales in 2023, and its follow-on Ultomiris, which was approved in 2018 and accounted for $3 billion in sales last year. AZ said that 10% to 20% of those who use C5 inhibitors such as ...

Novo Nordisk settles with 2 Florida venders of compounded Ozempic: Novo Nordisk has arrived at private settlements with two Florida merchants of intensified forms of the uber blockbuster semaglutide therapies Ozempic and Wegovy, the organization said on Friday. In June of last year, Novo recorded brand name encroachment claims against five dealers of knockoff renditions of the GLP-1 medications, which have seen soaring interest to battle weight reduction. Ekzotica Corp's. Restorative Laser Experts Drug Spa in Miami and Effinger Wellbeing's Nuvida Rx Weight reduction in Tallahassee are the initial two organizations to have settled their cases. As indicated by long-lasting directive orders, the dealers will quit utilizing Novo reserve and have consented to reveal for a considerable length of time that intensified variants of the medications have not gone through the security and viability norms expected by the FDA for supported drugs. "The litigants' unlawful showcasing ...

Invalidating a patent is a complex process that involves considering various legal standards and criteria. When it comes to patent invalidations, there are certain standards that courts in Europe and the United States adhere to.  In Europe, the primary legal standard applied in patent invalidations is the "European Patent Convention" (EPC), which governs the grant and enforcement of patents. Under the EPC, a patent can be invalidated if it does not meet the criteria of novelty, inventive step, and industrial applicability. The courts in Europe assess the patent by examining prior art, determining whether the claimed invention is new, non-obvious, and capable of industrial application. Additionally, the European courts also consider validity requirements such as sufficiency of disclosure, clarity, and added matter. In the United States, patent invalidation proceedings are conducted by the US Patent and Trademark Office (USPTO) through the "inter partes review" (IPR) ...

Patent prosecution in Jordan involves a series of steps to obtain patent protection for an invention within the country.  Here's an overview: 1. Patent Search:  Begin by conducting a patent search to ensure your invention is novel and not already patented in Jordan. This can be done through the Jordanian Patent Office (JPO) or online databases. 2.Draft a Patent Application:  Prepare a detailed patent application describing your invention's technical aspects, including drawings and claims. It's advisable to seek legal counsel or a patent attorney experienced in Jordanian patent law for assistance. 3.Filing the Application:  Submit your patent application to the JPO. Ensure it complies with the required format and includes all necessary documentation. Pay the filing fees. 4. Examination:  The JPO will examine your application to determine its patentability. This process may involve correspondence and amendments to the application if required. 5. Publication:...